Search
Human immunoglobulin G
go.drugbank.com/drugs/DB00028ApprovedInvestigationalIVIg contains the same distribution of IgG antibody subclasses as is found in the general human population.
Products: Gamimune N 5% (iv), Gamimune N 10% (iv)Zilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigational[L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication.
Synonyms: -GLUTAMYL-L-TYROSYL-L-PROLYL-(2S)-2-CYCLOHEXYLGLYCYL-N6-(3, -HYDROXY-, 15-ETHER WITH N-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.-ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-Chlorpromazine
go.drugbank.com/drugs/DB00477ApprovedInvestigationalVet approvedLike the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors.
Synonyms: 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine, 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-aminePantoprazole
go.drugbank.com/drugs/DB00213ApprovedInvestigationalPantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme … As the binding of pantoprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, pantoprazole's duration of antisecretory effect persists
Products: Nb-pantoprazoleSibutramine
go.drugbank.com/drugs/DB01105ApprovedIllicitWithdrawnSibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity.
Griseofulvin
go.drugbank.com/drugs/DB00400ApprovedVet approvedGriseofulvin may be given by mouth in the treatment of tinea infections.
Azacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigational[A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335] … It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine.
Fluoroestradiol F-18
go.drugbank.com/drugs/DB15690ApprovedInvestigationalacross metastases (i.e. to identify sites that no longer express ER) without the need for multiple biopsies. … [A203912] Fluoroestradiol F-18 was first granted FDA approval in May 2020, and will be developed by PETNET Solutions, Inc. and Zionexa USA under the brand name Cerianna.
Etacrynic acid
go.drugbank.com/drugs/DB00903ApprovedInvestigationalA compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules.
Categories: Non Potassium Sparing DiureticsDorzolamide
go.drugbank.com/drugs/DB00869ApprovedInvestigational[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. … Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and